Recent News

• 06.02.2026 - ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
• 06.01.2026 - Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
• 05.28.2026 - Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
• 05.27.2026 - Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
• 05.18.2026 - Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
• 05.15.2026 - Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
• 04.30.2026 - Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
• 04.28.2026 - Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

Recent Filings

• 05.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.28.2026 - EX-99.1 EX-99.1
• 05.27.2026 - EX-99.1 EX-99.1
• 05.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.18.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.18.2026 - EX-99.1 EX-99.1
• 05.15.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.15.2026 - EX-99.1 EX-99.1
• 05.01.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.30.2026 - EFFECT Notice of Effectiveness